Sanofi - American Depositary Shares (SNY)
$54.95
0.06 (0.11%)
SNY Stock Quote Delayed 30 Minutes
Analytics Keep Sanofi (SNY) Strong Buy Ranking
Currently, Sanofi SA (NYSE:SNY) has a Strong Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking SNY has had from Portfolio Grader for the last month.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
68.73B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.82M
Day's Range
$54.57 - $55.20
52-Week Range
$45.22 - $58.97
Dividend & Yield
$2.04 (3.71%)
SNY Stock Predictions, Articles, and Sanofi - American Depositary Shares News
After Johnson & Johnson (JNJ) Earnings Fail, Buy These Pharma Stocks Instead (RHHBY, SNY)
Shares of Johnson & Johnson slid in trading Tuesday after first-quarter earnings results disappointed. Here's where to turn in pharma today
3 Stocks to Watch on Monday: Tesla Inc (TSLA), Sanofi SA (ADR) (SNY) and Imagination Technologies Group plc (IMG)
Tesla (TSLA) beats estimates for Q1 deliveries, a Sanofi (SNY) drug delivers and Imagination Technologies (IMG) craters more than 60%.
Flexion Therapeutics Inc (FLXN) Stock Soars on Possible Sale to Sanofi
Flexion (FLXN) may soon be acquiring Sanofi (SNY) to boost its arthritis medications portfolio. Here's what you should know about the deal.
Amgen, Inc. (AMGN) Q4 Earnings Preview
Amgen (AMGN) reports Q4 earnings on Thursday, and if something does weigh on AMGN stock, it'll likely be one of these three factors.
Amgen, Inc.: Capture Stronger Upside in AMGN Stock
Uncertainty, optimism and good liquidity are good reasons to consider an Amgen spread in lieu of AMGN stock in front of earnings.
The Top 3 Places to Find High Yields
Things are finally turning around for income investors, and we've found these stocks to help maximize your gains
3 Stocks to Watch on Wednesday: Tesla Motors Inc (TSLA), Agile Therapeutics Inc (AGRX) and Regeneron Pharmaceuticals Inc (REGN)
Tesla Motors (TSLA) dips on a vehicle deliveries miss, Agile Therapeutics (AGRX) tanks on trial results and Regeneron (REGN) suffers a legal defeat.
Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma
Sanofi has a rough time during 2016, but after the U.S. presidential election and with several forward-looking decisions, SNY stock is a buy.
Regeneron Pharmaceuticals Inc (REGN) Stock Pops on Mixed Q3 Results
Regeneron Pharmaceuticals Inc (REGN) stock was up on Friday following mixed results in its earnings report for the third quarter of 2016.
PFE Stock: Ignore Pfizer Inc.’s Earnings Miss at Your Own Peril
Pfizer missed on earnings, and PFE stock slipped as a result. But even if you don't own Pfizer, you don't want to ignore what's happening there.
Sanofi SA (ADR) (SNY) Sues Merck & Co., Inc. (MRK) Over Multiple Patent Infringements
Sanofi (SNY) is suing Merck (MRK) for what it claims are several instances of patent infringement connected to its diabetes drug Lantus.
12 Pharmaceuticals Stocks to Sell Now
This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Warren Buffett’s 3 Best Dividend Stocks (VZ, SNY, GM)
In today's difficult long-term investing environment, Warren Buffett dividend stocks VZ, SNY and GM may be the best ideas in the market.
9 Pharmaceuticals Stocks to Sell Now
This week, 9 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Sanofi SA (ADR): SNY Pipeline Is Overflowing With Potential
With 18 launches scheduled by 2020, Sanofi stock is bound to get a hit or two. And given its 3.8% dividend, SNY is also a safe growth pick.
